ClinicalTrials.gg
CompletedNCT05498480RELATIVITY-111Updated Feb 20, 2024

Study of Relatlimab in Combination With Nivolumab in Chinese Participants

A Phase 1 interventional study of Relatlimab and Nivolumab in Advanced Solid Tumors, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Advanced Solid Tumors
  • Relatlimab
  • Nivolumab
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have histologic or cytological confirmation of an incurable solid that is advanced ( and/or unresectable) except for participants with primary central nervous system (CNS) tumors.
  • Participants must have received, and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (immune check inhibitor-experienced or non-experienced population may be included), if such a therapy exists. Participants who refuse or are ineligible for standard therapy will be allowed to enroll provided their refusal/ineligibility is documented in medical records.
  • (ECOG) 0 to 1.

Exclusion criteria

Exclusion Criteria:

  • Participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-cytotoxic T-lymphocyte-associated protein 4 [] or anti-programmed cell death protein 1 [anti-PD-1]/programmed death-ligand 1 [PD-L1] treatment or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (eg, hormone replacement after endocrinopathy).
  • Participants with an active, known, or suspected disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Prior treatment with LAG-3 targeted agents.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Cohort 1: Relatlimab Dose 1 + Nivolumab

    Biological: Relatlimab · Biological: Nivolumab

  • Experimental
    Cohort 2: Relatlimab Dose 2 + Nivolumab

    Biological: Relatlimab · Biological: Nivolumab

Interventions

  • BiologicalRelatlimab

    Specified dose on specified days

    Also known as: BMS-986016

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Opdivo

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Up to 123 Weeks

  2. Number of Participants with Immune-mediated Adverse Events (IMAEs)

    Time frame: Up to 123 Weeks

  3. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to 123 Weeks

  4. Number of Deaths

    Time frame: Up to 123 Weeks

  5. Number of Participants with AEs Leading to Discontinuation

    Time frame: Up to 123 Weeks

  6. Number of Participants with Dose-Limiting Toxicities (DLTs)

    Time frame: Up to 123 Weeks

  7. Number of Participants with Clinical Laboratory Abnormalities

    Time frame: Up to 123 Weeks

  8. Maximum Observed Plasma Concentration (Cmax) of Relatlimab

    Time frame: Up to 123 Weeks

  9. Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab

    Time frame: Up to 123 Weeks

  10. Trough-observed serum concentration (Ctrough) of Relatlimab

    Time frame: Up to 123 Weeks

Secondary outcomes

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator

    Time frame: Up to 123 Weeks

  2. Disease Control Rate (DCR) per RECIST v1.1 by Investigator

    Time frame: Up to 123 Weeks

  3. Duration of Response (DOR) per RECIST v1.1 by Investigator

    Time frame: Up to 123 Weeks

  4. Best Overall Response (BOR) per RECIST v1.1 by Investigator

    Time frame: Up to 123 Weeks

  5. Ctrough of Nivolumab

    Time frame: Up to 123 Weeks

  6. Observed Serum Concentration at End of Infusion (Ceoi) of Nivolumab

    Time frame: Up to 123 Weeks

  7. Percentage of Participants Positive for Anti-drug Antibodies (ADAs) to Relatlimab

    Time frame: Up to 123 Weeks

  8. Percentage of Participants Positive for ADAs to Nivolumab

    Time frame: Up to 123 Weeks

07

Study locations

1 site
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 201315, China
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jan 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 12, 2022
StartActual
Jul 27, 2022
Primary completionActual
Jan 18, 2024
CompletionActual
Jan 18, 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05498480
Responsible party
Sponsor
First posted
Aug 12, 2022
Start date
Jul 27, 2022
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024
Last update
Feb 20, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Nivolumab

Start the discussion